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Background: Noninvasive mechanical ventilation (NIMV) is an effective tool in treating 
patients with acute respiratory failure (ARF), since it reduces both the need for endotracheal 
intubation and the mortality in comparison with nonventilated patients. A particular issue is 
represented by the outcome of NIMV in patients referred to the emergency department for 
ARF and with a do-not-intubate (DNI) status because of advanced age or excessively critical 
conditions. This study evaluated long-term survival in a group of elderly patients with acute 
hypercapnic ARF who had a DNI order and who were successfully treated by NIMV .
Methods: The population consisted of 54 patients with a favorable outcome after NIMV for 
ARF. They were followed up for 3 years by regular control visits, with at least one visit every 
4 months, or as needed according to the patient’s condition. Of these, 31 continued NIMV at 
home and 23 were on long-term oxygen therapy (LTOT) alone.
Results: A total of 16 of the 52 patients had not survived at the 1-year follow-up, and another 
eight patients died during the 3-year observation, with an overall mortality rate of 30.8% after 
1 year and 46.2% after 3 years. Comparing patients who continued NIMV at home with those 
who were on LTOT alone, 9 of the 29 patients on home NIMV died (6 after 1 year and 3 after 
3 years) and 15 of the 23 patients on LTOT alone died (10 after 1 year and 5 after 3 years).
Conclusion: These results show that elderly patients with ARF successfully treated by NIMV 
following a DNI order have a satisfactory long-term survival.
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Introduction
Patients suffering from severe chronic obstructive pulmonary disease (COPD) at an 
advanced stage are quite frequently affected by chronic or acute respiratory failure.1 
The need to use ventilatory support is an indicator of a respiratory failure that influences 
survival.2 Noninvasive mechanical ventilation (NIMV), as showed by controlled trials 
and meta-analyses, is an effective tool in treating patients with respiratory failure.3–5 
In fact, NIMV is able to reduce: 1) the need for endotracheal intubation (ETI),6 
2) mortality rates, and 3) the duration of intensive care unit (ICU) or hospital stays.7 
These favorable outcomes have probably contributed to an increased use of NIMV in 
recent years.8,9 Nonetheless, there are special situations requiring further   investigation 
to indicate NIMV as a first choice procedure. In fact, the impact of NIMV in chronic 
hypercapnic respiratory failure in severe COPD is controversial, as indicated by ran-
domized controlled trials, particularly regarding survival.10 In addition, NIMV may 
have negative effects in acute respiratory failure, such as the delay in using ETI when 
the respiratory conditions require it.11,12International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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One of the particular aspects concerning the use of NIMV 
is represented by its outcome in patients who have a do-not-
intubate (DNI) status, which is dictated by their advanced 
age or by excessively critical and compromised conditions. 
We have previously demonstrated that elderly patients 
with acute respiratory failure due to COPD exacerbations 
(but also from restrictive thoracic disorders and multiorgan 
failure) and who had had a DNI order can be successfully 
treated by NIMV .13 This study addresses a 3-year follow-up 
of such patients.
Materials and methods
Patients
The study population has been previously described in 
detail.13 Briefly, 62 patients (30 males and 32 females; 
mean age 81 ± 4.8 years, range 79–91 years) entered the 
study, in the semi-intensive Respiratory Medicine Unit 
of Vimercate Hospital (Italy). All patients were receiving 
long-term   oxygen therapy (LTOT). Fifty patients had severe 
COPD, seven had restrictive thoracic disorders, and five had 
multiorgan failure. The inclusion criteria were: age $75 
years and a DNI order as defined by the unfavorable balance 
for ETI expressed by the emergency department physician 
(on the basis of advanced age and bad clinical status). The 
severity-of-illness classification was done by the Acute 
Physiology and Chronic Health Evaluation (APACHE) 
II,14 and the level of consciousness was established by the 
Glasgow Coma Score (GCS).15 Other considered parameters 
were PaO2/FiO2 (partial pressure of oxygen in arterial blood/
fraction of inspired oxygen), PaCO2 (partial pressure of 
carbon dioxide in arterial blood), pH, respiratory rate, heart 
rate, and blood pressure.
A total of 54 patients were successfully treated with 
NIMV; two did not respond to NIMV and were intubated (one 
survived). The remaining six patients died after a mean of 
9.9 days. Thus, the overall NIMV failure rate was 12.9%.
The 54 patients with a favorable outcome entered the 
3-year follow-up phase of the study with regular control 
visits, carried out at least once every 4 months, or as needed 
according to the patient’s conditions. Of these, 31 continued 
NIMV at home, based on the presence of chronic hypercapnic 
respiratory failure, and 23 remained on LTOT alone.
Statistical analysis
The number and characteristics of data required the use of 
both parametric and nonparametric tests. The student t-test 
(with the Welch variant) was used to analyze the two depen-
dent variables (survival at 1 year and 3 years) according to 
the considered parameters. Nonlinear logistic regression was 
used to analyze the likelihood of survival at 1 year and 3 years 
according to the patient’s age. The analysis of nonquantitative 
variables was performed by the Chi-square test. The statistical 
significance was set at a P value , 0.05.
Results
Out of the 54 patients, two (both belonging to the group 
continuing NIMV at home) were lost to follow-up, thus the 
analysis included 52 patients: 29 continuing NIMV and 23 on 
LTOT alone. A total of 16 of the 52 patients did not survive 
at the 1-year observation, none died during the 2nd year, and 
another eight patients did not survive at the 3-year observa-
tion, with an overall mortality rate of 30.8% after 1 year and 
46.2% after 3 years (Figure 1 upper panel). Of the 52 patients, 
41 (78.8%) had severe COPD: 23/29 (79%) in the NIMV 
group and 18/23 (78%) in the LTOT group. The mortality rate 
in COPD patients was superimposable to the overall group: 
12/41 (29.3%) after 1 year and 19/41 (46.4%) after 3 years. 
Comparing patients continuing NIMV at home with those 
on LTOT alone, 9 of the 29 patients continuing NIMV died 
(6 after 1 year and 3 after 3 years) and 15 of the 23 patients 
on LTOT alone died (10 after 1 year and 5 after 3 years) 
(Figure 1 lower panel). The mortality rates were 21% after 
1 year and 31% after 3 years in NIMV treated, while they 
were 43.5% after 1 year and 65.2% after 3 years in LTOT 
treated patients, respectively. None of these differences 
were statistically significant. Figure 2 shows the survival at 
1 and 3 years of follow-up analyzed by logistic regression 
according to patient’s age. Table 1 reports the dependence 
obtained from the considered parameters (the mean age, GCS, 
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Figure 1 Flowchart describing the study patients in the overall population (upper 
panel) and in patients treated with nIMV or only by LTOT, respectively (lower panel). 
Abbreviations:  nIMV,  noninvasive  mechanical  ventilation;  LTOT,  long-term 
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APACHE, blood gas parameters, inspiratory positive airway 
pressures (IPAPs) and expiratory positive airway pressures 
(EPAPs) set with NIMV. The dependence was significant 
only concerning age (P , 0.0001) and days of hospitaliza-
tion in pulmonary units after 3 years (P , 0.0001). The mean 
days of hospitalization during the 3-year follow-up were 
9.6 ± 11.6. The mean numbers were 2.1 ± 5.1 after 1 year 
and 4.2 ± 6.8 after 3 years in NIMV-treated, while they were 
1.7 ± 4.9 after 1 year and 1.6 ± 4.3 after 3 years in LTOT-
treated patients, respectively. The analysis of nonquantita-
tive variables by the Chi-square test showed no significant 
dependence for survival at 1 and 3 years.
Discussion
The development of acute respiratory failure (ARF) in 
patients with severe COPD or other respiratory diseases is 
a frequent cause of admission to emergency departments or 
to ICUs and is associated to significant mortality during the 
hospital stay and in the months following discharge.10,16 The 
long-term prognosis of these patients worsens if they need 
ventilatory support, either invasive or noninvasive.10,17 Not-
withstanding, NIMV represented a major advance in treat-
ing patients with acute and chronic respiratory failure, with 
evidence of improved short- and long-term outcome.5,10,18 
  Predictors of unsuccessful NIMV include an arterial 
pH , 7.25,19 the presence of relevant comorbidities,20 low 
scores in the severity-of-illness classification, as assessed by 
APACHE II, and the level of consciousness by the GCS,21 
and the lack of improvement in clinical and gas exchange 
measure within the first hour from starting NIMV .22
The first part of our study substantially confirmed these 
observation, in fact a low GCS, a high APACHE score at 
admission, and a low pH both after 1 and 12 hours of NIMV 
were negative prognostic factors for response to treatment.13 
However, the major aim of the study was to evaluate whether 
NIMV could be successful in patients who had received 
a DNI order, mainly because of an association of critical 
conditions and advanced age. Actually, the study included 
elderly patients (mean age of 81 years) with acute-on-chronic 
respiratory failure (all patients were on LTOT), and showed a 
low mortality rate (about 13%), that is particularly favorable 
in this setting. In fact, previous studies reported older age as 
a predictor of NIMV failure in patients with ARF.19 Also, 
in our study, age was a critical factor, since the mean age of 
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Figure 2 Survival after 1 and 3 years according to patient’s age.
Table 1 Parameters considered in analyzing survival
Variable 
(quantitative)
1 year survival 3 years survival
Correlation  
coefficient
P Correlation  
coefficient
P
Age -0.38 0.005 -0.49 0.000
gCS -0.06 0.693 0.01 0.964
APAChe 0.12 0.396 0.12 0.408
Days of 
hospitalization at 
entrance
-0.09 0.539 0.04 0.761
FiO2 -0.02 0.881 0.16 0.245
pO2 0.01 0.953 0.08 0.573
pCO2 0.15 0.279 0.17 0.236
ph 0.11 0.424 0.03 0.845
hCO3 0.19 0.188 0.11 0.421
pO2/FiO2 0.11 0.458 -0.03 0.856
FiO2 at discharge 0.20 0.148 0.19 0.189
pO2 at discharge 0.12 0.393 0.02 0.912
pO2/FiO2 at discharge -0.04 0.763 -0.17 0.230
pCO2 at discharge 0.16 0.258 0.18 0.200
ph at discharge -0.18 0.198 -0.12 0.392
hCO3 at discharge 0.06 0.659 0.16 0.244
IPAP 0.19 0.172 0.15 0.278
ePAP 0.26 0.063 0.19 0.175
Days of 
hospitalization 1 year 
in pulmonary units
-0.11 0.423 -0.13 0.341
Days of 
hospitalization 1 year 
in other units 
-0.11 0.427 -0.26 0.064
Days of 
hospitalization  
3 years in  
pulmonary units
0.42 0.002 0.51 0.000
Days of 
hospitalization 3 years  
in other units 
0.24 0.084 0.25 0.078
Total days of 
hospitalization
0.23 0.094 0.22 0.111
Abbreviations: APAChe, Acute Physiology and Chronic health evaluation; gCS, 
glasgow Coma Score; ePAP, expiratory positive airway pressure; FiO2, fraction of 
inspired oxygen; IPAP, inspiratory positive airway pressure; pCO2, carbon dioxide 
partial pressure; pO2, partial pressure of oxygen.International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
256
Scarpazza et al
the NIMV-nonresponders was significantly higher compared 
with that of the responders (87.4 years versus 80.5 years). 
Regardless of age, our findings were more favorable than in 
previous studies on COPD patients with DNI status, which 
reported a mortality rate ranging from 34% to 43%.23–25
However, age is an important issue to be considered, 
because the increasing duration of life in the general popu-
lation and the increasing life expectancy in COPD patients, 
mainly due to LTOT, make it common to find elder patients 
developing ARF. In these patients, the balance for ETI – as 
assessed by the emergency department physician – is often 
critical, leaving NIMV as the only treatment option. Indeed, 
to achieve a short-term low mortality rate with no evaluation 
of the long-term mortality should be of poor help in defining 
the actual role of NIMV in such patients.
This was the reason why we followed up the study 
patients. After 1 year, 69.2% of patients survived, and the 
survival rate was a rather satisfactory 53.8% after 3 years, 
this showing the importance of NIMV also in long-term 
survival of those patients. The survival rate we observed 
after 1 year is much higher than the rate of 16% reported 
by Bulow and Thorsager in their follow-up study of patients 
with a DNI.26 In our study, there was a clear difference in 
the mortality rate between the patients continuing NIMV at 
home (21% after 1 year and 31% after 3 years) as compared 
with those treated with LTOT alone (43.5% after 1 year and 
65.2% after 3 years). These rates were not significantly dif-
ferent by statistical analysis, but this lack of significance is 
due to the quite low number of patients. On the other hand, 
our patients were not randomized to undergo NIMV or 
LTOT, but received the most appropriate treatment based 
on their condition, NIMV being given to patients with 
chronic hypercapnic respiratory failure. Another notable 
finding is the low number of days of hospitalization in our 
population, which further reinforces the role of NIMV by 
highlighting its apparent cost-effectiveness. As showed by 
a study conducted in Spain, 3 months of NIMV at home 
saved 63 days of hospitalization and cut costs for the health 
care financier by 50%.27 The days of hospitalization are an 
essential measure for both costs and efficacy. In fact, in our 
study the number of days of hospitalization in pulmonary 
units at the 3-year observation was, together with age (which 
is quite obvious), the only significant factor associated with 
mortality (P , 0.0001).
In conclusion, this study shows that elderly patients 
with ARF successfully treated with NIMV following a DNI 
status have a satisfactory long-term survival, especially 
when they continue NIMV at home. This finding should 
encourage treatment by NIMV of patients with these 
characteristics.
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